HDFC Pharma and Healthcare Fund Direct Growth
Equity
Direct
Sector - Healthcare
NAV as on 22-10-2024
₹ 16.04
1D
Inception Returns
60.5%
/yr
About HDFC Pharma and Healthcare Fund Direct Growth
HDFC Pharma and Healthcare Fund Direct Growth is an equity fund. This fund was started on 4 October, 2023. The fund is managed by . The fund could potentially beat inflation in the long-run.
Key Parameters
- HDFC Pharma and Healthcare Fund Direct Growth has ₹1303 Cr worth of assets under management (AUM) as on Sep 2024 and is less than category average.
- The fund has an expense ratio 1.
Returns
HDFC Pharma and Healthcare Fund Direct Growth has given a CAGR return of 60.52% since inception. Over the last 1 year the fund has given a CAGR return of 64.19%.
Holdings
HDFC Pharma and Healthcare Fund Direct Growth has allocated its funds majorly in Cash Equivalent, Health, Basic Materials. Its top holdings are Sun Pharmaceuticals Industries Ltd, Divi's Laboratories Ltd, Cipla Ltd, Lupin Ltd, Ipca Laboratories Ltd
Taxation
As it is a sector - healthcare mutual fund the taxation is as follows:For short term (less than a year) capital gains will be taxed at 15%For long term (more than 1 year) capital gains will be taxed at 10% without indexation benefitDividends will always be taxed at slab rate. Gains upto Rs 1 lakh are exempt in case of long term.
Investment objective of HDFC Pharma and Healthcare Fund Direct Growth
To provide long-term capital appreciation by investing predominantly in equity and equity related securities of Pharma and healthcare companies. There is no assurance that the investment objective of the Scheme will be realized.
Minimum Investment and lockin period
Minimum investment for lump sum payment is INR 100.00 and for SIP is INR 100.00. HDFC Pharma and Healthcare Fund Direct Growth has no lock in period.
Historical NAV & Returns
Annualised
▲
▼
5690 people have invested ₹ 3.6Cr in HDFC Pharma and Healthcare Fund Direct Growth in the last three months
INDmoney Rank for HDFC Pharma and Healthcare Fund Direct Growth
Powered by IND quant engine
IND ranking is not available for this fund.
Among most bought funds within the category
No bad points found for this fund.
HDFC Pharma and Healthcare Fund Direct Growth Overview
| Expense ratio | 0.95% |
Benchmark | S&P BSE Healthcare PR |
| AUM | ₹1303 Cr |
| Inception Date | 4 October, 2023 |
| Min Lumpsum/SIP | ₹100/₹100 |
Exit Load | 1.0% |
| Lock In | No Lock-in |
TurnOver | 28.39% |
| STCG | Redeeming before 1 year, returns taxed at 20%. |
| LTCG | After 1 year, 12.5% tax on returns over ₹1.25 lakh/year. |
| Risk |   Very High Risk |
Trailing Returns
as on (22-Oct-24)
Fund Distribution
as on (30-Sep-24)
Small cap
35%
Large cap
33.5%
Mid cap
28.9%
Sector Allocation
Health
98.2%
Basic Materials
1.8%
All changes are between Jul'24 and Sep'24
- This fund’s returns stands at 2.65% whereas the fund’s underlying benchmark Nifty 500 returns stands at 2.04% as on Sep'24
- This fund outperformed Nifty 500 by 0.61% in Sep'24
- AUM of the fund stands at 1.2K Cr as of Sep'24
- AUM has remained same between Sep'24 and Aug'24
Top Stocks bought last month
Ipca Laboratories Ltd's allocation increased from 3.33% to 4.08%
Lupin Ltd's allocation increased from 4.78% to 5.32%
Dr. Lal PathLabs Ltd's allocation increased from 0.79% to 1.28%
Top Stocks sold last month
Sun Pharmaceuticals Industries Ltd's allocation decreased from 11.63 % to 11.56 %
Divi's Laboratories Ltd's allocation decreased from 7.55 % to 7.35 %
Cipla Ltd's allocation decreased from 5.54 % to 5.48 %
Mid Cap allocation has gone down from 32.5% to 28.9%
Large Cap allocation has gone up from 32.4% to 33.5%
Small Cap allocation has gone up from 31.7% to 35%
Cash allocation has gone down from 2.3% to 1.4%
Top 2 Sectors in September were Health, Basic Materials
Sep'24
Health
98%
Basic Materials
2%
Aug'24
Health
98%
Basic Materials
2%
See all
Top Growth Drivers | 1M Return |
|---|---|
 Divis Laboratories Ltd | 12.1% |
 Sun Pharmaceuticals Industries Ltd | 2.6% |
 Piramal Pharma Ltd | 1.7% |
Loading...
We are taking more time than usual
Fund House
HDFC Asset Management Co Ltd
Total Schemes
Total AUM
₹7.87L Cr
as on 30-Sep-2024
Address
HDFC Asset Management Company Limited,“HUL House”, 2nd Floor,,H.T. Parekh Marg,165-166, Backbay Reclamation,,Churchgate,
Phone
+912266316333
Website
cliser@hdfcfund.com
HDFC Pharma and Healthcare Fund Direct Growth Highlights
Very High Risk
Investors understand that their principal will be at Very High Risk
About the fund
This fund has delivered an average annual returns of 60.52% since inception which is more than its category average return of 27.26%
Fund Allocations
This fund has an allocation of 98.6% in Equity, 0% in Debt and 1.4% in Cash related instruments
AUM size ₹0 Cr
This fund has AUM of ₹0 Cr which is less than its category average of ₹ 2128 Cr
Expense Ratio 0.95%
This fund has an expense ratio of 0.95% which is less than its category average expense ratio of 1.41%
Frequently Asked Questions for HDFC Pharma and Healthcare Fund Direct Growth
The current NAV of HDFC Pharma and Healthcare Fund Direct Growth is ₹16.04 as on 22-Oct-2024.
Existing (Absolute + CAGR) as on 22-Oct-2024.
HDFC Pharma and Healthcare Fund Direct Growth | Absolute Returns | CAGR Returns |
1 Month Returns | 1.16% | 1.16% |
6 Month Returns | 32.89% | 32.89% |
1 Year Returns | 64.19% | 64.19% |
3 Years Returns | 0% | 0% |
5 Years Returns | 0% | 0% |
With INDmoney, the process of investing is very simple and involves zero commission.
- Click Buy on the fund name.
- Input the amount you are looking to invest.
- Select Lump Sum or SIP (Weekly, Monthly or Quarterly).
- Select your bank account and proceed with Payment.
0.95% as on September 2024
₹1303 Cr as on September 2024
Sun Pharmaceuticals Industries Ltd(11.56%), Divi's Laboratories Ltd(7.35%), Cipla Ltd(5.48%), Lupin Ltd(5.32%), Ipca Laboratories Ltd(4.08%) as on September 2024
The alpha ratio for the HDFC Pharma and Healthcare Fund Direct Growth for various period is as follows:
Fund Name | Alpha 1 Year | Alpha 3 Years | Alpha 5 Years |
HDFC Pharma and Healthcare Fund Direct Growth | - | - | - |
As on September 2024
The alpha for HDFC Pharma and Healthcare Fund Direct Growth is calculated against S&P BSE Healthcare PR. Higher alpha indicates that this fund has generated extra returns compared to the benchmark index. An alpha of 1.0 means the fund has outperformed its benchmark index by 1%.
The Beta ratio for the HDFC Pharma and Healthcare Fund Direct Growth for various period is as follows:
Fund Name | Beta 1 Year | Beta 3 Years | Beta 5 Years |
HDFC Pharma and Healthcare Fund Direct Growth | - | - | - |
As on September 2024
The Beta for HDFC Pharma and Healthcare Fund Direct Growth is calculated with S&P BSE Healthcare PR. Beta tells the volatility of the mutual fund relative to its benchmark. If the beta of a mutual fund is more than 1, then the mutual fund is more volatile than its benchmark. If beta is less than 1, then the mutual fund is less volatile than the benchmark.
The sharpe ratio for the HDFC Pharma and Healthcare Fund Direct Growth for various period is as follows:
Fund Name | Sharpe Ratio 1 Year | Sharpe Ratio 3 Years | Sharpe Ratio 5 Years |
HDFC Pharma and Healthcare Fund Direct Growth | - | - | - |
As on September 2024
The sharpe ratio for HDFC Pharma and Healthcare Fund Direct Growth is calculated with S&P BSE Healthcare PR. Sharpe ratio tells risk-adjusted-returns of the mutual fund. The higher a fund's Sharpe ratio, the better a fund's returns have been relative to the risk it has taken on.
The standard deviation for the HDFC Pharma and Healthcare Fund Direct Growth for various period is as follows:
Fund Name | Standard Deviation 1 Year | Standard Deviation 3 Years | Standard Deviation 5 Years |
HDFC Pharma and Healthcare Fund Direct Growth | - | - | - |
As on September 2024
Standard deviation tells the volatility of the returns of the mutual fund. The higher a fund's Standard deviation, the higher the volatility of the fund's returns.
The Exit load of HDFC Pharma and Healthcare Fund Direct Growth is 1%